The overall aim of biosimilar is to help contribute toward the reduction of cost for patients.
Imagine you’ve been living with rheumatoid arthritis for more than ten years.
At its core, HB 1366 boils down to two words: Trust and transparency.
HB 505 takes positive steps toward updating Ohio law to cover biologics and biosimilars in a
way that protects patients. As you know, unlike traditional chemical drugs, biologics are unique,
complex structures made from living cells that are not easily replicated. A small change or
difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.
Last year in March, 50-State Network advocate Anna Marie Meyer testified before the Oregon House of Representatives Committee on Health Care in opposition to HB 2026.